Jonathan R. Silva applies computational and biophysical methods to improve arrhythmia therapies.
His current projects include using holograms to guide ablation procedures and creating developing models to guide precision anti-arrhythmic drug prescription based on advanced molecular imaging data.
Jennifer Avari Silva, MD, associate professor of pediatrics; and Jonathan Silva, associate professor of biomedical engineering
Jonathan Silva, associate professor of biomedical engineering
The American Heart Association has recognized the McKelvey School of Engineering’s Jonathan Silva with its Established Investigator Award. The five-year $400,000 award will support his work into precision medicine for patients with irregular heartbeat.
Research from the lab of Jonathan Silva at the McKelvey School of Engineering leveraged computational models to analyze 70 years of arrhythmia-related data.
Washington University’s Jonathan Silva and Jeanne Nerbonne led a team that found that two drugs sometimes prescribed to treat arrhythmias affect heart atria and ventricles differently depending on the molecular composition of the sodium channels expressed.
A holographic display developed by researchers at Washington University in St. Louis improves physician accuracy when performing a procedure to treat irregular heartbeat.
Jonathan Silva, a biomedical engineer in the McKelvey School of Engineering at Washington University in St. Louis, has developed the first computational model that shows the molecular groundwork of a popular drug’s effectiveness in a variety of ways.
An international team, including faculty from the School of Engineering & Applied Science at Washington University in St. Louis, has used genetic phenotype to determine which patients would benefit the most from a commonly used drug treatment.
Irregular heartbeat — or arrhythmia — can have sudden and often fatal consequences. A biomedical engineering team at Washington University in St. Louis examining molecular behavior in cardiac tissue recently made a surprising discovery that could someday impact treatment of the life-threatening condition.